Loading...
Chugai Pharmaceutical Co., Ltd.
4519.T•JPX
HealthcareDrug Manufacturers - General
¥7619.00
¥287.00(3.91%)
Chugai Pharmaceutical Co., Ltd. (4519.T) Financial Performance & Statements
Review Chugai Pharmaceutical Co., Ltd.’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns to understand its financial health and growth.
Revenue Growth
5.33%
↑ 5.33%
Operating Income Growth
23.41%
↑ 23.41%
Net Income Growth
19.002%
↑ 19.002%
Operating Cash Flow Growth
9.19%
↑ 9.19%
Operating Margin
47.73%
↑ 47.73%
Gross Margin
70.98%
↑ 70.98%
Net Profit Margin
33.60%
↑ 33.60%
ROE
22.29%
↑ 22.29%
ROIC
30.17%
↑ 30.17%
Chugai Pharmaceutical Co., Ltd. (4519.T) Financial Statements
Explore quarterly and annual reports including balance sheet, income statement, cash flow for Chugai Pharmaceutical Co., Ltd. stock.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $300.60B | $315.68B | $315.91B | $236.95B |
| Cost of Revenue | $94.30B | $84.22B | $87.94B | $72.95B |
| Gross Profit | $206.30B | $231.46B | $227.97B | $164.00B |
| Gross Profit Ratio | $0.69 | $0.73 | $0.72 | $0.69 |
| R&D Expenses | $52.20B | $44.92B | $42.94B | $41.27B |
| SG&A Expenses | $32.40B | $25.88B | $25.32B | $21.18B |
| Operating Expenses | $82.90B | $70.80B | $68.25B | $62.45B |
| Total Costs & Expenses | $177.20B | $155.27B | $156.19B | $135.40B |
| Interest Income | $0.00 | $0.00 | $480.00M | $15.00M |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $25.18B | $400.00M | $400.00M | $400.00M |
| EBITDA | $148.69B | $159.24B | $159.20B | $100.29B |
| EBITDA Ratio | $0.49 | $0.50 | $0.50 | $0.42 |
| Operating Income | $123.40B | $160.66B | $159.72B | $101.55B |
| Operating Income Ratio | $0.41 | $0.51 | $0.51 | $0.43 |
| Other Income/Expenses (Net) | $2.10B | -$1.82B | $480.00M | -$169.00M |
| Income Before Tax | $125.50B | $158.84B | $158.80B | $99.89B |
| Income Before Tax Ratio | $0.42 | $0.50 | $0.50 | $0.42 |
| Income Tax Expense | $33.90B | $49.34B | $46.94B | $25.49B |
| Net Income | $91.60B | $109.50B | $111.86B | $74.40B |
| Net Income Ratio | $0.30 | $0.35 | $0.35 | $0.31 |
| EPS | $55.64 | $66.54 | $67.98 | $45.22 |
| Diluted EPS | $55.64 | $66.53 | $67.97 | $45.21 |
| Weighted Avg Shares Outstanding | $1.65B | $1.65B | $1.65B | $1.65B |
| Weighted Avg Shares Outstanding (Diluted) | $1.65B | $1.65B | $1.65B | $1.65B |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan